Texas Permanent School Fund Corp lowered its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 2.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,262 shares of the medical instruments supplier’s stock after selling 307 shares during the period. Texas Permanent School Fund Corp’s holdings in West Pharmaceutical Services were worth $5,726,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Sunbelt Securities Inc. purchased a new position in shares of West Pharmaceutical Services during the first quarter worth $25,000. RVW Wealth LLC acquired a new position in West Pharmaceutical Services in the 3rd quarter valued at about $38,000. First Horizon Advisors Inc. increased its stake in West Pharmaceutical Services by 37.4% during the first quarter. First Horizon Advisors Inc. now owns 147 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 40 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of West Pharmaceutical Services during the third quarter worth about $53,000. Finally, Addison Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 37.9% in the third quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 39 shares during the period. 91.23% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on WST shares. Jefferies Financial Group upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their target price for the stock from $323.00 to $536.00 in a report on Wednesday, February 7th. Stephens decreased their target price on West Pharmaceutical Services from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, October 27th. Finally, StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $412.20.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services stock opened at $409.64 on Monday. The stock has a market cap of $30.31 billion, a P/E ratio of 55.28, a price-to-earnings-growth ratio of 4.04 and a beta of 1.05. The company has a current ratio of 3.70, a quick ratio of 2.89 and a debt-to-equity ratio of 0.05. The company has a fifty day simple moving average of $358.15 and a 200-day simple moving average of $367.59. West Pharmaceutical Services, Inc. has a 12-month low of $264.52 and a 12-month high of $415.73.
West Pharmaceutical Services Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 7th. Investors of record on Wednesday, January 31st were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.20%. The ex-dividend date was Tuesday, January 30th. West Pharmaceutical Services’s payout ratio is 10.80%.
Insider Activity at West Pharmaceutical Services
In related news, CAO Chad Winters sold 1,013 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $349.00, for a total value of $353,537.00. Following the transaction, the chief accounting officer now directly owns 1,270 shares of the company’s stock, valued at approximately $443,230. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.13% of the stock is currently owned by corporate insiders.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Five stocks we like better than West Pharmaceutical Services
- Transportation Stocks Investing
- Uber quadruples EPS estimates, but is growth decelerating?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 stocks set to benefit from record Valentine’s Day spending
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.